Wide-transcriptome analysis and cellularity of bone marrow CD34+/lin- cells of patients with chronic-phase chronic myeloid leukemia at diagnosis vs. 12 months of first-line nilotinib treatment

Cancer Biomark. 2017 Dec 12;21(1):41-53. doi: 10.3233/CBM-170209.

Abstract

Background: Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder with heterogeneous biological and clinical features. The biomolecular mechanisms of CML response to tyrosine-kinase inhibitors are not fully defined.

Objective: We undertook a gene expression profiling (GEP) study of selected bone marrow (BM) CD34+/lin- cells of chronic-phase CML patients at diagnosis and after 12 months of TKI nilotinib to investigate molecular signatures characterizing both conditions.

Publication types

  • Multicenter Study

MeSH terms

  • Antigens, CD34 / blood
  • Bone Marrow Cells / metabolism*
  • Bone Marrow Cells / pathology
  • Gene Expression Profiling / methods*
  • Gene Expression Regulation, Leukemic / drug effects
  • Humans
  • Leukemia, Myeloid, Chronic-Phase / blood
  • Leukemia, Myeloid, Chronic-Phase / drug therapy*
  • Leukemia, Myeloid, Chronic-Phase / genetics*
  • Leukocyte Count
  • Protein-Tyrosine Kinases / therapeutic use
  • Pyrimidines / therapeutic use*
  • Time Factors
  • Treatment Outcome

Substances

  • 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide
  • Antigens, CD34
  • Pyrimidines
  • Protein-Tyrosine Kinases